Todd D. Schell - Publications

Affiliations: 
Pennsylvania State University, State College, PA, United States 
Area:
Immunology, Microbiology Biology

53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD. Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. Oncoimmunology. 8: e1539614. PMID 30713799 DOI: 10.1080/2162402X.2018.1539614  0.32
2018 Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, Drabick JJ, Schell TD. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology. 7: e1405205. PMID 29399407 DOI: 10.1080/2162402X.2017.1405205  0.32
2018 Ward-Kavanagh LK, Kokolus KM, Cooper TK, Lukacher AE, Schell TD. Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors. Cancer Immunology, Immunotherapy : Cii. PMID 29332158 DOI: 10.1007/s00262-018-2115-2  0.32
2017 Cladel NM, Budgeon LR, Balogh KK, Cooper TK, Brendle SA, Christensen ND, Schell TD, Hu J. Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer. Scientific Reports. 7: 16932. PMID 29208932 DOI: 10.1038/s41598-017-17089-4  0.32
2017 Maru S, Jin G, Schell TD, Lukacher AE. TCR stimulation strength is inversely associated with establishment of functional brain-resident memory CD8 T cells during persistent viral infection. Plos Pathogens. 13: e1006318. PMID 28410427 DOI: 10.1371/journal.ppat.1006318  0.32
2016 Koller KM, Mackley HB, Liu J, Wagner H, Talamo G, Schell TD, Pameijer C, Neves RI, Anderson B, Kokolus KM, Mallon CA, Drabick JJ. Improved Survival and Complete Response Rates in Patients with Advanced Melanoma Treated with Concurrent Ipilimumab and Radiotherapy versus Ipilimumab Alone. Cancer Biology & Therapy. 0. PMID 27905824 DOI: 10.1080/15384047.2016.1264543  0.32
2016 Koller KM, Wang W, Schell TD, Cozza EM, Kokolus KM, Neves RI, Mackley HB, Pameijer C, Leung A, Anderson B, Mallon CA, Robertson G, Drabick JJ. Malignant melanoma-The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology. 106: 25-54. PMID 27637351 DOI: 10.1016/j.critrevonc.2016.04.010  0.32
2016 Li G, Liu D, Cooper TK, Kimchi ET, Qi X, Avella DM, Li N, Yang QX, Kester M, Bart Rountree C, Kaifi JT, Cole DJ, Rockey DC, Schell TD, Staveley-O'Carroll KF. Successful Chemoimmunotherapy against Hepatocellular Cancer in a Novel Murine Mode. Journal of Hepatology. PMID 27520877 DOI: 10.1016/j.jhep.2016.07.044  0.32
2016 Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka W, George MR, Zeng H, Zheng H. T-cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T cell Exhaustion and Poor Clinical Outcome in AML Patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26763253 DOI: 10.1158/1078-0432.CCR-15-2626  0.84
2015 Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biology & Therapy. 16: 662-70. PMID 25806780 DOI: 10.1080/15384047.2015.1026507  0.84
2015 Koscsó B, Gowda K, Schell TD, Bogunovic M. Purification of dendritic cell and macrophage subsets from the normal mouse small intestine. Journal of Immunological Methods. 421: 1-13. PMID 25796561 DOI: 10.1016/j.jim.2015.02.013  0.84
2015 Cozza EM, Cooper TK, Budgeon LR, Christensen ND, Schell TD. Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunology, Immunotherapy : Cii. 64: 325-36. PMID 25408469 DOI: 10.1007/s00262-014-1635-7  0.84
2015 Richie JP, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition. 54: 251-63. PMID 24791752 DOI: 10.1007/s00394-014-0706-z  0.84
2014 Ward-Kavanagh LK, Zhu J, Cooper TK, Schell TD. Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer. Cancer Immunology Research. 2: 777-88. PMID 24801834 DOI: 10.1158/2326-6066.CIR-13-0164  0.84
2014 Rytelewski M, Meilleur CE, Yekta MA, Szabo PA, Garg N, Schell TD, Jevnikar AM, Sharif S, Singh B, Haeryfar SM. Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase. Plos One. 9: e90439. PMID 24587363 DOI: 10.1371/journal.pone.0090439  0.84
2013 Goodwin EM, Zhong Q, Abendroth CS, Ward-Kavanagh LK, Schell TD, Cooper TK. Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse. Comparative Medicine. 63: 338-41. PMID 24209969  0.84
2012 Watson AM, Mylin LM, Thompson MM, Schell TD. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 189: 5549-60. PMID 23175697 DOI: 10.4049/jimmunol.1102221  0.84
2012 Wilson JJ, Pack CD, Lin E, Frost EL, Albrecht JA, Hadley A, Hofstetter AR, Tevethia SS, Schell TD, Lukacher AE. CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. Journal of Immunology (Baltimore, Md. : 1950). 188: 4340-8. PMID 22447978 DOI: 10.4049/jimmunol.1103727  0.84
2012 Maleki Varek S, Harding MJ, Waithman J, Zanker D, Shivji AN, Rytelewski M, Mazzuca DM, Yekta MA, Chen W, Schell TD, Haeryfar SMM. Differential regulation of simultaneous antitumor and alloreactive CD8 + T-cell responses in the same host by rapamycin American Journal of Transplantation. 12: 233-239. PMID 22026814 DOI: 10.1111/j.1600-6143.2011.03811.x  0.84
2012 Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (Baltimore, Md.). 55: 141-52. PMID 21898502 DOI: 10.1002/hep.24652  0.84
2011 Campbell C, Zhang R, Haley JS, Liu X, Loughran T, Schell TD, Albert R, Thakar J. Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach. Frontiers in Physiology. 2: 32. PMID 21808621 DOI: 10.3389/fphys.2011.00032  0.84
2010 Hu J, Schell TD, Peng X, Cladel NM, Balogh KK, Christensen ND. Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines. Journal of Vaccines & Vaccination. 1. PMID 21572916 DOI: 10.4172/2157-7560.1000101  0.84
2010 Drabick JJ, Schell TD. Poking CD40 for cancer therapy, another example of the Goldilocks effect. Cancer Biology & Therapy. 10: 994-6. PMID 21057206 DOI: 10.4161/cbt.10.10.13976  0.84
2010 Fateh S, Schell TD, Gingrich R, Neves RI, Drabick JJ. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer Biology & Therapy. 10: 1091-7. PMID 20930514 DOI: 10.4161/cbt.10.11.13452  0.84
2010 Tatum AM, Watson AM, Schell TD. Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation. Journal of Immunology (Baltimore, Md. : 1950). 185: 2763-72. PMID 20660711 DOI: 10.4049/jimmunol.0903920  0.84
2009 Manuel SL, Schell TD, Acheampong E, Rahman S, Khan ZK, Jain P. Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. Journal of Leukocyte Biology. 86: 1205-16. PMID 19656902 DOI: 10.1189/jlb.0309172  0.84
2009 Hu J, Schell TD, Peng X, Cladel NM, Balogh KK, Christensen ND. Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits Procedia in Vaccinology. 1: 4-14. DOI: 10.1016/j.provac.2009.07.003  0.84
2008 Ryan CM, Staveley-O'Carroll K, Schell TD. Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 906-20. PMID 18832997 DOI: 10.1097/CJI.0b013e318189f155  0.84
2008 Tatum AM, Mylin LM, Bender SJ, Fischer MA, Vigliotti BA, Tevethia MJ, Tevethia SS, Schell TD. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. Journal of Immunology (Baltimore, Md. : 1950). 181: 4406-17. PMID 18768900  0.84
2008 de Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS, van Tinteren H, Mesman EM, Song JY, Schumacher TN. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. Journal of Immunology (Baltimore, Md. : 1950). 181: 2563-71. PMID 18684947  0.84
2008 Tagaram HR, Watson AM, Lemonnier FA, Staveley-O'Carroll K, Tevethia SS, Schell TD. An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants. Virology. 376: 183-90. PMID 18402997 DOI: 10.1016/j.virol.2008.02.033  0.84
2008 Yorty JL, Tevethia SS, Schell TD. Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunology, Immunotherapy : Cii. 57: 883-95. PMID 18004562 DOI: 10.1007/s00262-007-0424-y  0.84
2007 Otahal P, Knowles BB, Tevethia SS, Schell TD. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. Journal of Immunology (Baltimore, Md. : 1950). 179: 6686-95. PMID 17982058  0.84
2007 Mylin LM, Schell TD, Epler M, Kusuma C, Assis D, Matsko C, Smith A, Allebach A, Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology. 364: 155-68. PMID 17368499 DOI: 10.1016/j.virol.2007.02.007  0.84
2006 Hu J, Peng X, Schell TD, Budgeon LR, Cladel NM, Christensen ND. An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. Journal of Immunology (Baltimore, Md. : 1950). 177: 8037-45. PMID 17114477  0.84
2006 Otahal P, Schell TD, Hutchinson SC, Knowles BB, Tevethia SS. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 177: 3089-99. PMID 16920946  0.84
2006 Sheil JM, Frankenberry MA, Schell TD, Brundage KM, Barnett JB. Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors. Environmental Health Perspectives. 114: 1059-64. PMID 16835059 DOI: 10.1289/ehp.8774  0.84
2006 Ryan CM, Schell TD. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. Journal of Immunology (Baltimore, Md. : 1950). 177: 255-67. PMID 16785521  0.84
2005 Otahal P, Hutchinson SC, Mylin LM, Tevethia MJ, Tevethia SS, Schell TD. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. Journal of Immunology (Baltimore, Md. : 1950). 175: 700-12. PMID 16002665  0.84
2004 Barton LF, Runnels HA, Schell TD, Cho Y, Gibbons R, Tevethia SS, Deepe GS, Monaco JJ. Immune defects in 28-kDa proteasome activator gamma-deficient mice. Journal of Immunology (Baltimore, Md. : 1950). 172: 3948-54. PMID 15004203  0.84
2004 Schell TD. In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. Journal of Virology. 78: 1751-62. PMID 14747540 DOI: 10.1128/JVI.78.4.1751-1762.2004  0.84
2003 Stanic AK, Shashidharamurthy R, Bezbradica JS, Matsuki N, Yoshimura Y, Miyake S, Choi EY, Schell TD, Van Kaer L, Tevethia SS, Roopenian DC, Yamamura T, Joyce S. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. Journal of Immunology (Baltimore, Md. : 1950). 171: 4539-51. PMID 14568927  0.84
2003 Anglen CS, Truckenmiller ME, Schell TD, Bonneau RH. The dual role of CD8+ T lymphocytes in the development of stress-induced herpes simplex encephalitis. Journal of Neuroimmunology. 140: 13-27. PMID 12864968 DOI: 10.1016/S0165-5728(03)00159-0  0.84
2003 Staveley-O'Carroll K, Schell TD, Jimenez M, Mylin LM, Tevethia MJ, Schoenberger SP, Tevethia SS. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 171: 697-707. PMID 12847236  0.84
2002 Schell TD, Mylin LM, Tevethia SS, Joyce S. The assembly of functional beta(2)-microglobulin-free MHC class I molecules that interact with peptides and CD8(+) T lymphocytes. International Immunology. 14: 775-82. PMID 12096037  0.84
2001 Schell TD, Tevethia SS. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8+ T lymphocytes by the endogenous tumor antigen1 Journal of Immunology. 167: 6947-6956. PMID 11739514  0.84
2001 Schell TD, Lippolis JD, Tevethia SS. Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen Cancer Research. 61: 873-879. PMID 11221873  0.84
2001 Schell TD, Tevethia SS. Cytotoxic T lymphocytes in SV40 infections Methods in Molecular Biology (Clifton, N.J.). 165: 243-256. PMID 11217391  0.84
2000 Mylin LM, Schell TD, Roberts D, Epler M, Boesteanu A, Collins EJ, Frelinger JA, Joyce S, Tevethia SS. Quantitation of CD8+ T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes Journal of Virology. 74: 6922-6934. PMID 10888631 DOI: 10.1128/JVI.74.15.6922-6934.2000  0.84
2000 Schell TD, Knowles BB, Tevethia SS. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Research. 60: 3002-12. PMID 10850449  0.84
1999 Schell TD, Mylin LM, Georgoff I, Teresky AK, Levine AJ, Tevethia SS. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. Journal of Virology. 73: 5981-93. PMID 10364350  0.84
1998 Fu TM, Mylin LM, Schell TD, Bacik I, Russ G, Yewdell JW, Bennink JR, Tevethia SS. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. Journal of Virology. 72: 1469-81. PMID 9445050  0.84
1994 Sheil JM, Schell TD, Shepherd SE, Klimo GF, Kioschos JM, Paterson Y. Presentation of a horse cytochrome c peptide by multiple H-2b class I major histocompatibility complex (MHC) molecules to C57BL/6- and bm1-derived cytotoxic T lymphocytes: Presence of a single MHC anchor residue may confer efficient peptide-specific CTL recognition European Journal of Immunology. 24: 2141-2149. PMID 7522163  0.84
Show low-probability matches.